Cargando…

Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays

In the United States (U.S.), a hepatitis E virus (HEV) seroprevalence between 6 and 21% has been described, with a decreasing trend. We aimed to investigate HEV infection in the U.S. population from 2009 to 2016, and examine the differences in seroprevalence using different assays. We used data from...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisano, María Belén, Campbell, Christopher, Anugwom, Chimaobi, Ré, Viviana Elizabeth, Debes, José D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355204/
https://www.ncbi.nlm.nih.gov/pubmed/35930611
http://dx.doi.org/10.1371/journal.pone.0272809
_version_ 1784763241694494720
author Pisano, María Belén
Campbell, Christopher
Anugwom, Chimaobi
Ré, Viviana Elizabeth
Debes, José D.
author_facet Pisano, María Belén
Campbell, Christopher
Anugwom, Chimaobi
Ré, Viviana Elizabeth
Debes, José D.
author_sort Pisano, María Belén
collection PubMed
description In the United States (U.S.), a hepatitis E virus (HEV) seroprevalence between 6 and 21% has been described, with a decreasing trend. We aimed to investigate HEV infection in the U.S. population from 2009 to 2016, and examine the differences in seroprevalence using different assays. We used data from the National Health and Nutrition Examination Survey (NHANES-CDC) to estimate HEV seroprevalence and analyze demographic variables related to the infection. Additionally, we compared 4 serological tests used. The estimated HEV seroprevalence between 2009–2016 was 6.1% (95% CI: 5.6%-7.0%) for IgG and 1.02% (0.8%-1.2%) for IgM. Higher HEV IgG prevalences were found in older people, females, non-Hispanic Asians and those born outside of the U.S. The in-house immunoassay and the Wantai HEV-IgG ELISA presented the highest sensitivity values in the tested population. The highest specificity values corresponded to the DSI-EIA-ANTI-HEV-IgG assay. The kappa statistical values showed concordances no greater than 0.64 between the assays. HEV prevalence in our study was similar to previously reported, and a decline in the prevalence was observed through the NHANES assessments (from 1988 to 2016). The sensitivity and specificity of the assays varied widely, making comparisons difficult and highlighting the need to develop a gold standard assay.
format Online
Article
Text
id pubmed-9355204
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-93552042022-08-06 Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays Pisano, María Belén Campbell, Christopher Anugwom, Chimaobi Ré, Viviana Elizabeth Debes, José D. PLoS One Research Article In the United States (U.S.), a hepatitis E virus (HEV) seroprevalence between 6 and 21% has been described, with a decreasing trend. We aimed to investigate HEV infection in the U.S. population from 2009 to 2016, and examine the differences in seroprevalence using different assays. We used data from the National Health and Nutrition Examination Survey (NHANES-CDC) to estimate HEV seroprevalence and analyze demographic variables related to the infection. Additionally, we compared 4 serological tests used. The estimated HEV seroprevalence between 2009–2016 was 6.1% (95% CI: 5.6%-7.0%) for IgG and 1.02% (0.8%-1.2%) for IgM. Higher HEV IgG prevalences were found in older people, females, non-Hispanic Asians and those born outside of the U.S. The in-house immunoassay and the Wantai HEV-IgG ELISA presented the highest sensitivity values in the tested population. The highest specificity values corresponded to the DSI-EIA-ANTI-HEV-IgG assay. The kappa statistical values showed concordances no greater than 0.64 between the assays. HEV prevalence in our study was similar to previously reported, and a decline in the prevalence was observed through the NHANES assessments (from 1988 to 2016). The sensitivity and specificity of the assays varied widely, making comparisons difficult and highlighting the need to develop a gold standard assay. Public Library of Science 2022-08-05 /pmc/articles/PMC9355204/ /pubmed/35930611 http://dx.doi.org/10.1371/journal.pone.0272809 Text en © 2022 Pisano et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Pisano, María Belén
Campbell, Christopher
Anugwom, Chimaobi
Ré, Viviana Elizabeth
Debes, José D.
Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays
title Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays
title_full Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays
title_fullStr Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays
title_full_unstemmed Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays
title_short Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays
title_sort hepatitis e virus infection in the united states: seroprevalence, risk factors and the influence of immunological assays
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355204/
https://www.ncbi.nlm.nih.gov/pubmed/35930611
http://dx.doi.org/10.1371/journal.pone.0272809
work_keys_str_mv AT pisanomariabelen hepatitisevirusinfectionintheunitedstatesseroprevalenceriskfactorsandtheinfluenceofimmunologicalassays
AT campbellchristopher hepatitisevirusinfectionintheunitedstatesseroprevalenceriskfactorsandtheinfluenceofimmunologicalassays
AT anugwomchimaobi hepatitisevirusinfectionintheunitedstatesseroprevalenceriskfactorsandtheinfluenceofimmunologicalassays
AT revivianaelizabeth hepatitisevirusinfectionintheunitedstatesseroprevalenceriskfactorsandtheinfluenceofimmunologicalassays
AT debesjosed hepatitisevirusinfectionintheunitedstatesseroprevalenceriskfactorsandtheinfluenceofimmunologicalassays